GlassScriptPhysician profile
Robert A Mcdermott
NPI 1841261385
$650.91
in general payments reported to CMS, 2019-2025
13 companies · $39.73 in 2025
The $39.73 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.58 · 2020: $72.76 · 2021: $56.80 · 2022: $58.62 · 2023: $227 · 2024: $99.34 · 2025: $39.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $366.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $144.66 | 2021-2025 | Xolair |
| Astrazeneca Pharmaceuticals LP | $123.15 | 2019-2025 | Breztri, Tezspire, Fasenra |
| Genzyme Corporation | $103.66 | 2019-2024 | |
| Glaxosmithkline, LLC. | $78.70 | 2019-2023 | Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $39.39 | 2019-2024 | |
| Csl Behring | $28.01 | 2023 | Hizentra |
| Sunovion Pharmaceuticals INC. | $23.01 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $21.62 | 2020 | |
| Biocryst US Sales Co., LLC | $21.50 | 2023 | Orladeyo |
| Incyte Corporation | $20.58 | 2022 | |
| Kaleo, INC. | $19.62 | 2020 | |
| Sanofi-Aventis U.S. LLC | $14.50 | 2021 | |
| Optinose US, INC. | $12.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mcdermott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.